Cargando…

624. Molecular Characterization of Baseline Enterobacteriaceae and Pseudomonas aeruginosa from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial

BACKGROUND: ASPECT-NP, a phase 3, randomized, double-blind, multicenter trial, evaluated ceftolozane/tazobactam (C/T) 3 g q8h vs. meropenem 1 g q8h for 8–14 days in adults for treatment of ventilated nosocomial pneumonia. Baseline Gram-negative (GN) isolates from patients were tested for mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castanheira, Mariana, Johnson, Matthew G, Yu, Brian, Huntington, Jennifer A, Carmelitano, Patricia, Bruno, Christopher, Rhee, Elizabeth G, Motyl, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811271/ http://dx.doi.org/10.1093/ofid/ofz360.692

Ejemplares similares

2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)
por: Huntington, Jennifer A, et al.
Publicado: (2019)

2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP)
por: Wunderink, Richard G, et al.
Publicado: (2019)

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
por: Lu, Qin, et al.
Publicado: (2014)

Rapid identification of carbapenemase-producing Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii using a modified Carba NP test
por: Bakour, S., et al.
Publicado: (2015)

339 An International, Multicenter, Retrospective Study of Nosocomial Pneumonia due to Pseudomonas aeruginosa
por: Micek, Scott, et al.
Publicado: (2014)

An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance
por: Micek, Scott T, et al.
Publicado: (2015)

624. Probability of Target Attainment of Ceftolozane/Tazobactam Among Adult Patients with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Secondary to Pseudomonas aeruginosa in Latin America
por: Okuma, Aline, et al.
Publicado: (2022)

Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
por: Martin-Loeches, Ignacio, et al.
Publicado: (2023)

Club Cell protein: a candidate diagnostic biomarker of Pseudomonas aeruginosa nosocomial pneumonia
por: Moroz, V, et al.
Publicado: (2014)

Spontaneous Nosocomial Pseudomonas aeruginosa Meningitis Presenting as Trismus
por: Parr, C. J., et al.
Publicado: (2017)

The Transcriptional Regulator Np20 Is the Zinc Uptake Regulator in Pseudomonas aeruginosa
por: Ellison, Matthew L., et al.
Publicado: (2013)

Antibiotic susceptibility pattern, risk factors, and prediction of carbapenem-resistant Pseudomonas aeruginosa in patients with nosocomial pneumonia
por: Liu, Yao, et al.
Publicado: (2023)

Imipenem-Resistant Pseudomonas aeruginosa: Risk Factors for Nosocomial Infections
por: Onguru, Pinar, et al.
Publicado: (2008)

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States (US) Medical Centers (2013–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

Correction: The Transcriptional Regulator Np20 Is the Zinc Uptake Regulator in Pseudomonas aeruginosa
por: Ellison, Matthew L., et al.
Publicado: (2013)

Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial
por: Lodise, Thomas, et al.
Publicado: (2020)

Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition
por: Morales, Eva, et al.
Publicado: (2012)

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States (US) Medical Centers Stratified by Infection Type (2015–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

Clinical aspects and predictors of mortality of Pseudomonas aeruginosa pneumonia in a cohort of critically ill patients
por: De Pascale, G, et al.
Publicado: (2011)

2062. Evaluation of Susceptibility Testing Methods for Fosfomycin Against Enterobacteriaceae and Pseudomonas aeruginosa
por: De La Cadena, Elsa Piedad, et al.
Publicado: (2018)

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
por: Timsit, Jean-François, et al.
Publicado: (2021)

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)
por: Pfaller, Michael A., et al.
Publicado: (2017)

Predictors of Clinical Success in the Treatment of Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Nosocomial Pneumonia (NP)
por: Shorr, Andrew F., et al.
Publicado: (2015)

Utilizing Infantile Spasm Seizure Activity as a Baseline Vital in the Setting of Acute Pseudomonas aeruginosa Pneumonia
por: Thompson, Landon R, et al.
Publicado: (2023)

Role of Imipenem-resistant metallo-beta-lactamase positive pseudomonas aeruginosa carriers in nosocomial infections
por: Yogeesha, Babu K. V., et al.
Publicado: (2013)

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020
por: Sader, Helio S., et al.
Publicado: (2021)

Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
por: Caffrey, Aisling R., et al.
Publicado: (2022)

Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae
por: Bang, Ji Hwan, et al.
Publicado: (2013)

Prevalence of Virulence Genes Among Bulgarian Nosocomial and Cystic Fibrosis Isolates of Pseudomonas Aeruginosa
por: Mitov, Ivan, et al.
Publicado: (2010)

Evaluation of Risk Factors for Antibiotic Resistance in Patients with Nosocomial Infections Caused by Pseudomonas aeruginosa
por: Sonmezer, Meliha Cagla, et al.
Publicado: (2016)

Nosocomial Infections with IMP-19−Producing Pseudomonas aeruginosa Linked to Contaminated Sinks, France
por: Amoureux, Lucie, et al.
Publicado: (2017)

SAT624 Neurosarcoidosis Presenting With Panhypopituitarism
por: Niedzialkowska, Ewelina Marta, et al.
Publicado: (2023)

Rates of gastrointestinal tract colonization of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa in hospitals in Saudi Arabia
por: Abdalhamid, B., et al.
Publicado: (2016)

1592. In Vitro Activity of Ceftolozane/Tazobactam (C/T) Against Enterobacteriaceae and Pseudomonas aeruginosa Circulating in Chile
por: Rivas, Lina M, et al.
Publicado: (2019)

Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation
por: Dai, Yuanyuan, et al.
Publicado: (2021)

Fungal Planet description sheets: 558–624
por: Crous, P.W., et al.
Publicado: (2017)

Comparison of severity of illness scoring systems for patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa
por: Marra, Alexandre R, et al.
Publicado: (2006)

Carbapenem-hydrolyzing metallo-beta-lactamase from a nosocomial isolate of Pseudomonas aeruginosa in France.
por: Poirel, L, et al.
Publicado: (2000)

P44 Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol
por: Stevenson, D. R., et al.
Publicado: (2022)

Prevalence of antibiotic resistance and virulent factors in nosocomial clinical isolates of Pseudomonas aeruginosa from Panamá
por: Sambrano, Héctor, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p8364cam2uf5jm5s2jqg7ed418